Abstract
Introduction
Chronic kidney disease (CKD) is a clinical syndrome characterized by abnormality in kidney structure or function. In the United States, the prevalence of CKD as diagnosed by estimated glomerular filtration rate (eGFR) and proteinuria is 11.5% [1] . According to the Chinese Epidemiology Surveillance in 2012, CKD prevalence in Chinese adults was 10.8%, with a total case number of 120 million [2] . Elevated inflammatory markers are important risk factors for CKD [3] . In animal models, inflammation process has been proved to be essentially involved in the progression of kidney diseases [4] [5] [6] [7] [8] . Tonelli et al. [9] found that higher baseline C-reactive protein (CRP) would accelerate kidney function failure in CKD patients.
So far, studies on the association between CRP and CKD have generated conflicting results. Some studies reported that CRP, fibrinogen, and serum albumin were related to rapid reduction of eGFR [10, 11] . Hiramoto et al. [12] found that in CKD patients, CRP concentration was significantly associated with kidney function recession. Kugler et al. [13] found that elevated CRP significantly increased risk of CKD. However, other studies reported no association. Studies by Sarnak et al. [14] found that higher CRP was not an independent risk factor for nondiabetic kidney disease progression. Shankar et al. [15] found that increase in CRP would not result in higher CKD risk. Previous studies on the relationship between high-sensitivity CRP (hs-CRP) and CKD were mostly based on single hs-CRP measurement, whereas hs-CRP concentration is affected by many factors, such as metabolic factors (e.g., obesity, diabetes), environmental factors, and underlying infections. A single measure of hs-CRP might not accurately indicate the association between inflammatory markers and CKD. Moreover, there are few longitudinal studies using hs-CRP to predict CKD incident risk in the general population. The Kailuan Study (registration No. ChiCTR-TNC-11001489) is a cohort study on risk factors for cardiovascular diseases based on a community population. Participants received biennial health examinations on cardio health risk factors including serum creatinine (sCr), urinary protein, and hs-CRP, which enables our study to gain insight into the association between cumulative hs-CRP exposure and CKD risk.
Materials and Methods

Study Population
From 2006 to 2007, 11 hospitals in the Kailuan community, including Kailuan General Hospital and its affiliated hospitals, recruited and provided health examinations for current and former employees of the Kailuan Company. Hence, the health providers provided following health examinations every 2 years. We included participants who participated in the [2006] [2007] [2008] [2009] , and 2010-2011 health examinations to observe the association between three-time hs-CRP exposure level and future CKD incidence. This study followed the Declaration of Helsinki and was approved by the Ethical Board of Kailuan General Hospital.
The inclusion criteria of this study were: those from the Kailuan Study who participated in the [2006] [2007] [2008] [2009] , and 2010-2011 health examinations, had complete hs-CRP data, had complete sCr and urinary protein data, and consented and signed to participate in
Assessment of Covariates
Smoking was defined as at least 1 cigar/day in the past 1 year. Drinking was defined as consuming 100 mL hard liquor (ethanol content > 50%) daily in the past 1 year. Active physical activity was defined as ≥3 times/week physical exercise, with ≥30 min every time. Height and weight were measured by trained nurses, and body mass index (BMI) was calculated as weight (kg)/height (m 2 ). Hypertension was diagnosed as systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg or using antihypertensive drugs currently. Diabetes was diagnosed as fasting blood glucose (FBG) ≥7.0 mmol/L or using antidiabetic drugs currently. Hyperlipidemia was diagnosed as total cholesterol (TC) ≥5.2 mmol/L or triglyceride ≥1.7 mmol/L or low-density lipoprotein cholesterol ≥3.4 mmol/L or using lipid-lowering agents currently [17] .
Cumulative Exposure to hs-CRP
We defined hs-CRP ≥3.0 mg/L as exposed to inflammation. We classified participants into 4 groups: the nonexposed group had all 3 hs-CRP measurements < 3.0 mg/L, the 1-exposed group had hs-CRP ≥3.0 mg/L in 1 out of 3 examinations, the 2-exposed group had hs-CRP ≥3.0 mg/L in 2 out of 3 examinations, and the 3-exposed group had hs-CRP ≥3.0 mg/L in all 3 examinations.
Calculation of eGFR
We estimated GFR according to the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula [18] . 
Outcomes
We defined incident CKD as first occurrence of either eGFR < 60 mL/min/1.73 m 2 or positive proteinuria [19] . Follow-up of each participants started at the examination date in 2010-2011 and ended at the last health examination (2014-2015) or the incidence of CKD.
Statistical Analysis
Health examination data were recorded by trained staff and uploaded to Kailuan General Hospital Server. Data were analyzed in SAS 9.2 (SAS Institute, Inc., Cary, NC, USA). Quantitative variables were presented as mean ± standard deviation, using one-way analysis of variance for test of difference between groups and list significance test for pairwise comparison. Categorical variables were presented as number and percentage (%), using chisquare test for intergroup difference. We compared incidence rate of CKD across cumulative hs-CRP exposed groups and further used Cox proportional hazards model to calculate hazard ratio (HR) and 95% confidence interval (CI). All tests were two-sided, and p value < 0.05 was considered as statistically significant.
To exclude confounding factors such as acute inflammation and use of lipid-lowering agents, antihypertensive drugs, or antidiabetic drugs, we excluded participants that met these criteria, respectively, and conducted sensitivity analysis in the Cox proportional hazards model. Fig. 1 ). Mean age was 53 ± 11 years. There were 26,994 men (76.7%). After categorizing the study population into exposure groups (the nonexposed, 1-exposed, 2-exposed, and 3-exposed groups), we found that participants in the higher exposure groups tended to have higher age, baseline SBP, DBP, BMI, FBG, and TC. They also had higher prevalence of hypertension and diabetes. Between-group comparisons showed significant difference (p < 0.001, Table 1 ), while for baseline eGFR, between-group comparisons showed nonsignificant difference (p = 0.214, Table 1 ). In addition, we compared group average and interquartile range of hs-CRP concentration in three examinations across exposure groups (p < 0.001, Table 1 ).
Results
Baseline Characteristics
Incidence of CKD in hs-CRP Exposure Groups
During an average follow-up time of 3.96 ± 0.48 years, there were 2,882 incident CKD cases, including 1,582 cases of eGFR < 60 mL/min/1.73 m 2 and 1,388 cases of positive 
proteinuria. There was a trend for higher CKD incidence rate associated with more hs-CRP exposure. The incidence rate for 1-exposed, 2-exposed, and 3-exposed cumulative hs-CRP groups were 20.6, 33.2, and 42.0 per 1,000 person-years, respectively. Incidence rates of eGFR < 60 mL/min/1.73 m 2 and proteinuria were individually positively associated with hs-CRP exposure (p < 0.05, Table 2 ).
Cox Proportional Hazards Model for CKD Risk Factors
In the Cox proportional hazards model, we used cumulative hs-CRP exposure as explanatory variable (nonexposed group as reference) and eGFR < 60 mL/min/1.73 m 2 , proteinuria, and overall CKD as outcome, respectively. Model 1 was adjusted for sex and age, model 2 was further adjusted for baseline SBP, BMI, FBG, TC, physical activity, smoking, alcohol drinking, and use of antihypertensive, antidiabetic, and lipid-lowering drugs, based on model 1, while model 3 was further adjusted for baseline (2006) hs-CRP, based on model 2. We found that, compared to the nonexposed group, the hs-CRP 3-exposed group had higher HR of 1.26 (95% CI: 1.01-1.58) for eGFR < 60 mL/min/1.73 m 2 , 2.29 (95% CI: 1.88-2.78) for proteinuria, and 1.72 (95% CI: 1.48-1.99) for CKD (p for trend < 0.01, Table 3 ).
In addition, we used baseline (2006) hs-CRP as explanatory variable and adjusted as in model 2. The HR (95% CI) was 1.02 (1.01-1.02) for proteinuria and 1.01 (1.00-1.01) for CKD; for eGFR < 60 mL/min/1.73 m 2 , the HR (95% CI) was 1.00 (0.99-1.01) (online supplementary 
Sensitivity Analysis
In the sensitivity analyses, exclusion of the participants with hs-CRP > 10 mg/L, diabetes, hypertension, and taking antihypertensive drugs, hypoglycemic agents, and lipid-lowering medication generated similar results compared to nonexposed group and cumulative hs-CRP 3-exposed group in relation to odds of having CKD or high or very high CKD risk, whereas no significant difference in HR was found for eGFR < 60 mL/min/1.73 m 2 (Table 4) . We also have conducted several sensitive analyses between cumulative hs-CRP and chronic kidney disease among subgroup population (smokers/nonsmokers, hypertensive/ non-hypertensive, diabetes mellitus/non-diabetes mellitus) (supplementary Table S2 , DOI: 10.6084/m9.figshare.9960035). The results showed that, compared to the nonexposed group, the participants with cumulative hs-CRP-exposed groups had higher risk for CKD. Furthermore, the CKD risks in the population of nonsmokers, non-hypertensive, non-diabetes mellitus, and non-hyperlipidemia were much higher than in the population with smoking, hypertensive, diabetes, and hyperlipidemia (p < 0.01). 
Discussion
This study showed that incidence of CKD and proteinuria was positively associated with cumulative hs-CRP exposure. Incidence rate of CKD and proteinuria in the cumulative hs-CRP 3-exposed group was twice and three times higher, respectively, compared to that of the nonexposed group. A trend for higher incidence rate of eGFR < 60 mL/min/1.73 m 2 with increased hs-CRP exposure was also identified. Previous study found that in a metabolically healthy obese (MHO) population, during 3.9 years of follow-up, CKD incidence in the MHO/ hs-CRP ≥0.2 mg/L group (10.3%) was significantly greater than that of the MHO/hs-CRP < 0.2 mg/L group (6.5%) [20] . Hemmelgarn et al. [21] found that, compared to patients with lowered eGFR but negative urinary protein, patients characterized by severe proteinuria but normal eGFR had much worse clinical outcomes. By comparing incidence rate in a prospective cohort, we found that higher cumulative hs-CRP exposure status was significantly associated with higher incidence rate of CKD, especially proteinuria. This association was more consistent for proteinuria and kidney damage.
Moreover, we found that cumulative exposure to high hs-CRP was a risk factor for kidney damage. Compared to the nonexposed group, the 3-exposed group had a 0.72 times higher risk of CKD; for proteinuria, the risk was 1.29 times higher and for eGFR < 60 mL/min/1.73 m 2 , 0.26 times higher. More exposure to high hs-CRP was positively associated with higher risk of kidney damage and proteinuria. The study by Stuveling et al. [22] found that in nondiabetic population, higher CRP concentration was strongly related with lower eGFR (odds ratio = 1.9; 95% CI: 1.3-2.9). Other studies reported that in older populations, high CRP concentration was associated with higher sCr, lower eGFR, and higher CKD risk [10, 23, 24] . Meanwhile, a previous study also found no association between baseline hs-CRP and incident CKD [15] . However, these studies were mostly focused on a single measure of hs-CRP, without considering the fluctuation and cumulative effect of hs-CRP across a long time span. Therefore, this study is more informative in studying the association between cumulative measures of hs-CRP and incident CKD.
Due to the large sample size and relatively long follow-up period, to test the stability of our models, we used log likelihood ratio test and Akaike information criterion to compare model fitness of hs-CRP markers. The result showed that after adjustment for baseline hs-CRP, adding cumulative exposure to hs-CRP into the model generated better prediction. To minimize confounding factors such as acute inflammation, infectious disease, hypertension, diabetes, and medication, we excluded participants with these clinical features and found even higher risk for kidney damage, with a 70% higher risk of the 3-exposed group compared to nonexposure. Kugler et al. [13] , in a historical prospective study on the association between CRP and CKD, found that higher CRP was positively associated with CKD risk, and this prediction value was more significant in population with diabetes, hypertension, and eGFR between 60 and 90 mL/min/1.73 m 2 . However, these findings were not in concordance with our result. We had conducted several sensitive analyses between cumulative hs-CRP and CKD among subgroup population, and it was found that the CKD risks in the population of nonsmokers, non-hypertensive, non-diabetes mellitus, and nonhyperlipidemia were much higher. In Kugler et al.'s research [13] , where CRP values for each subject were calculated as a mean for all visits, some of the data was retrospectively analyzed and was prone to bias. Our Kailuan Study consists of longitudinal studies in general population. So it is much more meaningful to monitor hs-CRP in healthy population in order to decrease the CKD risk. We look forward to more prospective cohort studies for further validation.
Several potential mechanism might explain the association between inflammation and CKD. First, epidemiology studies showed that elevated CRP concentration was associated with atherosclerosis [25] . Atherosclerosis and glomerulosclerosis are the most common pathways for many types of kidney damage. Mesangium enlargement shares many similar characteristics as over-proliferation of pulmonary arterial smooth muscle cells [26] . CRP might reflect the inflammation process involved in glomerulosclerosis. Second, inflammatory cascade induced by macrophages and monocytes could damage tubular interstitial cells. This is a common characteristic in many non-immune kidney diseases (e.g., diabetes, hypertension, anemia, and proteinuria) [27] . Third, in human endothelial cells, CRP triggers adhesion molecules to produce interleukin 6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1). These could increase inflammatory level in the plaque by attracting more monocytes and lymphocytes, which in turn induce endothelial damage, inflammation, and kidney damage. Fourth, risk factors for kidney function loss, such as obesity, smoking, hypertension, diabetes, and inadequate physical activity, are commonly associated with elevated CRP and inflammatory status [28, 29] .
This study found that cumulative exposure to high hs-CRP was associated with risk of CKD. However, there are limitations to be addressed. First, this study had a relatively short follow-up time of an average 3.96 years, but since this is an ongoing cohort study with biannual examinations and follow-ups every half year, we can possibly relook at and test our results in the future. Also, urinary protein test was based on a single urine sample in a semiquantitative way instead of quantitative measure using 24-hour urine samples. This might cause misclassification of CKD. However, due to its higher sensitivity (93.3%) and specificity (91.6%) in comparison to quantitative method [30] and its easy, fast, and cheap nature, the semiquantitative method has been widely used in large-scale epidemiology studies. Second, The data of eGFR were calculated indirectly from sCr measurement during the healthy examination. The participants with abnormal level of sCr would be recommended to visit the nephrology clinic and clarified a diagnosis of chronic kidney disease by monitoring sCr level. However, we have no detailed description of acute kidney disease, this is a limitation of our study. Last but not least, participants of this study might not be representative of other populations. This finding needs to be tested in future studies.
This study highlights cumulative exposure to high hs-CRP as a risk factor for incident CKD. Controlling hs-CRP at a relatively low level could possibly reduce risk of kidney damage. Future studies should focus on the association between CRP and incidence and progression of CKD, and whether low hs-CRP exposure might predict improvement in kidney function in longitudinal cohorts. These studies might provide evidence for targeting hs-CRP as wholebody inflammatory markers for CKD prevention and treatment.
Conclusions
In a large-scale community-based prospective cohort study (n = 35,194), cumulative exposure to hs-CRP was associated with a subsequent increased risk of CKD and was of great value to risk prediction. This study highlights cumulative exposure to high hs-CRP as a risk factor for incident CKD.
